← All trials
NCT00042289
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2003
- Primary completion
- Jun 1, 2019
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 1786
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Boston UniversityStudy chair
- National Institutes of Health (NIH)Collaborator
Drugs studied
- levofloxacin
- efavirenz
- aminosalicylic acid
- linezolid
- capreomycin
- clofazimine
- cycloserine
- ethambutol
- etravirine
- ethinyl estradiol
- dolutegravir
- tenofovir
- ritonavir
- rifampin
- drospirenone
- desogestrel
- nevirapine
- atazanavir
- pretomanid
- pyrazinamide
- lopinavir
- terizidone
- darunavir
- ethionamide
- protionamide
- moxifloxacin
- isoniazid
- amikacin
- bedaquiline
- ofloxacin
- cobicistat
- elvitegravir
- kanamycin
- delamanid
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.